VALIDAR EL USO DE FIBRINA RICA EN PLAQUETAS Y LEUCOCITOS (L-PRF) EN CABALLOS PARA AUMENTAR LOS PROCESOS DE REGENERACIÓN TISULAR

Abstract

A second generation of PRP has been recently proposed as a biomaterial for human surgery. This substance is named leukocyte and platelet rich fibrin (L-PRF) and is obtained from venous blood collected in tubes without anticoagulant and immediately centrifuged at low acceleration. This is a production process in which platelet activation occurs gradually when platelets contact with the tube wall and fibrin polymerizes. Several cells are trapped within the fibrin mesh, predominantly platelets and leucocytes and investigations performed have led to elucidate the role of these components in the tissue healing process._x000D_ These preliminary studies in equine blood have shown that several growth factors including PDGF-BB, IGF-1, TGF-β1 are released from the clots in a sustained manner over a period of 2-3 weeks of incubation, that the clots can be moulded into different shapes and adapted for potential different uses in surgery acting as scaffolds for wound healing augmentation. Although, L-PRF is frequently used in human maxillofacial surgery and for the treatment of recalcitrant chronic wounds there is no basic or clinical information about this biomaterial in equine regenerative medicine._x000D_ This study contributes about PRF basic biology in horses and supports biologic translational information to humans and other mammals. TNF-α, IL-4 and IL-1ra were produced by resident leukocytes from PRF clots, whereas PDGF-BB and TGF-β1 were mostly produced by platelet degranulation, although these findings were suggestive that both GF were also produced by leukocytes enmeshed in PRF clots. These findings demonstrate a paramount role of leukocytes in wound healing, either induced or modified by PRF clots in mammals. Furthermore, it is important to consider that TNF-α should be considered a regulatory and consequently beneficial cytokine in PRF clots, because it increases the release of anti-inflammatory cytokines from this biomaterial._x000D_ The hypotheses were corroborated, because PRF clots produced and released cytokines and GFs over a long term and no practical differences for protein release pattern were noticed between equine PRF clots obtained with the two centrifugation protocols evaluated. However, it is recommendable to incorporate the clinical use of serum supernatant which is a by-product obtained during PRF processing, because it is extremely rich in anabolic GF.

Date of Award	28 Sept 2017
Original language	Spanish
Supervisor	Marta Prades Robles (Director) & Jorge Uriel Carmona Ramírez (Director)